-
Front Oncol: The effect of chemotherapy on the overall survival of patients with metastatic prostate cancer
Time of Update: 2021-12-04
This real-world data study shows that chemotherapy can improve the overall survival of patients with metastatic prostate cancer .
This real-world data study shows that chemotherapy can improve the overall survival of patients with metastatic prostate cancer .
-
JNB: Research on the mechanism of formononetin inhibiting cervical cancer
Time of Update: 2021-12-04
The expression level of protein/RNA , histopathology, and immunohistochemistry were verified in vivo to explore the anti-tumor effect of formononetin on cervical cancer in vitro and in vivo .
Co-immunoprecipitation experiments showed that formononetin inhibits the expression of PD-L1 protein by interfering with the interaction between MYC and STAT3 .
-
NEJM: How effective is pembrolizumab in treating persistent, recurrent or metastatic cervical cancer?
Time of Update: 2021-12-04
In patients with persistent, recurrent, or metastatic cervical cancer who received chemotherapy with or without bevacizumab, the progression-free survival and overall survival of the pembrolizumab group were significantly longer than those of the placebo group .
-
J Clin Oncol: Nivolumab combined with Ipilimumab in the treatment of advanced melanoma
Time of Update: 2021-12-04
The results show that compared with ipilimumab, nivolumab Combination of ipilimumab or ipilimumab alone can significantly improve the clinical prognosis of advanced melanoma; and the efficacy of nivolumab combined with ipilimumab is better than that of nivolumab monotherapy .
-
Circulation: The Changxing team of West Lake University uses base editing to bring hope to cure Duchenne muscular dystrophy
Time of Update: 2021-12-04
Recently, Life Sciences, University of the West Lake Chang Xing research group in Circulation published online entitled: Therapeutic Exon Skipping Via A CRISPR-Guided Cytidine Deaminase rescues dystrophic an In Vivo Cardiomyopathy research papers .
-
Front Oncol: First-line immunotherapy may improve the prognosis of patients with EGFR-mutant NSCLC after using EGFR-TKI
Time of Update: 2021-12-04
There are limited data on the use of immune checkpoint inhibitors (ICIs) to treat patients with advanced non-small cell lung cancer ( NSCLC ) with epidermal growth factor receptor (EGFR) mutations .
-
Front Oncol: The efficacy of first-line and second-line treatment of advanced cholangiocarcinoma, and the effect of dose reduction on the efficacy
Time of Update: 2021-12-04
Analyze the overall survival (OS) , progression-free survival (PFS) and toxicity of all patients , especially those with adjusted chemotherapy doses .
(OS) , progression-free survival (PFS) and toxicity, especially in patients with adjusted chemotherapy doses .
-
The cover of Science Advances is a multi-unit collaboration with Zhejiang University. Zhou Min/Tao Wei uses Spirulina as a drug delivery vehicle for the treatment of colon cancer and colitis
Time of Update: 2021-12-04
On November 24, 2021, Zhou Min of Zhejiang University and Tao Wei of Harvard Medical School jointly published a research paper entitled "Orally deliverable strategy based on microalgal biomass for intestinal disease treatment" in Science Advances (this paper is also the cover paper of the current issue) , The study reported a multifunctional formula based on the spiral-shaped cyanobacterium Spirulina platensis (SP), which contains curcumin (SP@Curcumin) for the treatment of colon cancer and colitis, two intestinal diseases .
-
Lancet Oncol: Efficacy of dabrafenib combined with trametinib in BRAFV600E mutation-positive glioma
Time of Update: 2021-12-04
2 months in the low-grade glioma cohort, 9 patients (69%) achieved objective remissions, including 1 complete remission, 6 partial remissions, and 2 minor remissions .
2 months in the low-grade glioma cohort, 9 patients (69%) achieved objective remissions, including 1 complete remission, 6 partial remissions, and 2 minor remissions .
-
Clin Cancer Res: Efficacy, safety and biomarkers of torepalizumab in second-line treatment of metastatic urothelial cancer
Time of Update: 2021-12-04
Progression-free survival rate of PD-L1 positive or negative patientsProgression-free survival rate of PD-L1 positive or negative patientsThe objective response rate of patients with PD-L1 positive and high TMB value (≥10 mutations/Mb) was significantly higher than that of PD-L1 negative patients (42% vs 17%; p=0.
-
Front Oncol: Based on the SEER database to compare the survival results of radical prostatectomy (PR) and radiotherapy (RT) for metastatic prostate cancer
Time of Update: 2021-12-04
In the unmatched cohort, the Cox proportional hazards model showed no significant difference between the two groups of CSM or ACM (CSM: HR = 0.
statistics Prognostic analysis Prognostic analysisThe Kaplan-Meier survival curve showed that the 10-year survival rates of the RP and RT groups before PSM were 70.
-
Nature: The fatty acids in this widely consumed vegetable oil will promote cancer metastasis
Time of Update: 2021-12-04
Based on this discovery, the research team has developed a therapy to block cancer cell metastasis, and is expected to launch human clinical trials in the next few years .
-
Nature Nanotechnology: I was stunned. Cancer cells learned 36 tricks. They took money from the bottom and stole the mitochondria of immune cells to achieve immune escape.
Time of Update: 2021-12-04
Faced with the suppression of the firepower of the immune system, will cancer cells evolve a mechanism to weaken them and then outwit the immune system?In this study, the research team first noticed mitochondrial transfer, an easily overlooked intercellular communication phenomenon .
-
2021 ASH is the first to see Professor Zhang Xian sharing CAR-T treatment experience and cutting-edge progress
Time of Update: 2021-12-04
In recent years, chimeric antigen receptor T cell (CAR-T) therapy has achieved breakthrough results in the field of hematological tumors, and CAR-T-related new drugs have also been launched in China, but there are still many problems that urgently need to be further improved in clinical research, such as Persistence, the influencing factors of curative effect and how to choose effective targets and other issues .
-
Nature Biomedical Engineering: Put a silica coat on cancer cells to make cancer vaccines, which can eradicate tumors and can be stored for a long time
Time of Update: 2021-12-04
Nature Biomedical Engineering Cancer vaccines from cryogenically silicified tumour cells functionalized with pathogen-associated molecular patternsThe study demonstrated that cancer vaccines can be made by low-temperature silicification of tumor cells, storing tumor antigens in a nano-silica layer, and then modifying the silicified surface with pathogen-related molecular patterns .
-
Merck and Dragonfly are working together again!
Time of Update: 2021-12-04
Li Fuying as Vice President & Head of the Pharmaceutical Affairs DepartmentMedClub broke the news on November 29, 2021/MedClub PR News/-- Dragonfly Therapeutics recently announced that Merck has obtained a license from Dragonfly for its second TriNKET™ immunotherapy drug candidate .
-
In addition to thrombolysis and lowering blood pressure to treat dementia, can ta also make oral ulcer patients eat it?
Time of Update: 2021-12-04
The purpose of this study is to study the changes in mouse body weight, information and epithelial cell regeneration to determine the role of crude nattokinase extract NCE in the treatment of oral mucositis .
-
HER2 and ER are not expressed, and there are 8 popular targets for triple-negative breast cancer
Time of Update: 2021-12-04
← Swipe left and right to view, click [Read the original text] to learn more → Triple Negative Breast Cancer (TNBC) is a very aggressive and heterogeneous basal-like tumor, accounting for 15-20% of breast cancer cases, three classics Targets: estrogen receptor (ER), progesterone receptor (progesterone receptor) and human epidermal growth factor receptor 2 (HER2) lack expression .
-
2021 ASH is very promising. Regarding the continuous treatment of multiple myeloma, the results of the US MM-6 study have been updated!
Time of Update: 2021-12-04
Introduction As an academic feast that has attracted much attention in the field of hematology, the 63rd American Society of Hematology (ASH) Annual Meeting will be held in Atlanta, USA on December 1
-
J Clin Oncol: The treatment compliance of patients with early-onset colorectal cancer is better than that of late-onset patients, but the prognosis is worse!
Time of Update: 2021-12-04
Compared with patients with late-onset colorectal cancer, patients with early-onset colorectal cancer have a significantly worse cancer-specific prognosis, especially for high-risk stage III colorectal cancer patients: the 3-year recurrence-free survival rate is lower (54% vs 65%) ; Hazard ratio [HR] 1.
